Cargando…

Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology

INTRODUCTION//BACKGROUND: The lack of standardization of the currently used commercial anti-rubella IgG antibody assays leads to frequent misinterpretation of results for samples with low/equivocal antibody concentration. The use of alternative approaches in rubella serology could add new informatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Haralambieva, Iana H., Gibson, Michael J., Kennedy, Richard B., Ovsyannikova, Inna G., Warner, Nathaniel D., Grill, Diane E., Poland, Gregory A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690594/
https://www.ncbi.nlm.nih.gov/pubmed/29145521
http://dx.doi.org/10.1371/journal.pone.0188149
_version_ 1783279633425235968
author Haralambieva, Iana H.
Gibson, Michael J.
Kennedy, Richard B.
Ovsyannikova, Inna G.
Warner, Nathaniel D.
Grill, Diane E.
Poland, Gregory A.
author_facet Haralambieva, Iana H.
Gibson, Michael J.
Kennedy, Richard B.
Ovsyannikova, Inna G.
Warner, Nathaniel D.
Grill, Diane E.
Poland, Gregory A.
author_sort Haralambieva, Iana H.
collection PubMed
description INTRODUCTION//BACKGROUND: The lack of standardization of the currently used commercial anti-rubella IgG antibody assays leads to frequent misinterpretation of results for samples with low/equivocal antibody concentration. The use of alternative approaches in rubella serology could add new information leading to a fuller understanding of rubella protective immunity and neutralizing antibody response after vaccination. METHODS: We applied microarray technology to measure antibodies to all rubella virus proteins in 75 high and 75 low rubella virus-specific antibody responders after two MMR vaccine doses. These data were used in multivariate penalized logistic regression modeling of rubella-specific neutralizing antibody response after vaccination. RESULTS: We measured antibodies to all rubella virus structural proteins (i.e., the glycoproteins E1 and E2 and the capsid C protein) and to the non-structural protein P150. Antibody levels to each of these proteins were: correlated with the neutralizing antibody titer (p<0.006); demonstrated differences between the high and the low antibody responder groups (p<0.008); and were components of the model associated with/predictive of vaccine-induced rubella virus-specific neutralizing antibody titers (misclassification error = 0.2). CONCLUSION: Our study supports the use of this new technology, as well as the use of antibody profiles/patterns (rather than single antibody measures) as biomarkers of neutralizing antibody response and correlates of protective immunity in rubella virus serology.
format Online
Article
Text
id pubmed-5690594
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-56905942017-11-30 Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology Haralambieva, Iana H. Gibson, Michael J. Kennedy, Richard B. Ovsyannikova, Inna G. Warner, Nathaniel D. Grill, Diane E. Poland, Gregory A. PLoS One Research Article INTRODUCTION//BACKGROUND: The lack of standardization of the currently used commercial anti-rubella IgG antibody assays leads to frequent misinterpretation of results for samples with low/equivocal antibody concentration. The use of alternative approaches in rubella serology could add new information leading to a fuller understanding of rubella protective immunity and neutralizing antibody response after vaccination. METHODS: We applied microarray technology to measure antibodies to all rubella virus proteins in 75 high and 75 low rubella virus-specific antibody responders after two MMR vaccine doses. These data were used in multivariate penalized logistic regression modeling of rubella-specific neutralizing antibody response after vaccination. RESULTS: We measured antibodies to all rubella virus structural proteins (i.e., the glycoproteins E1 and E2 and the capsid C protein) and to the non-structural protein P150. Antibody levels to each of these proteins were: correlated with the neutralizing antibody titer (p<0.006); demonstrated differences between the high and the low antibody responder groups (p<0.008); and were components of the model associated with/predictive of vaccine-induced rubella virus-specific neutralizing antibody titers (misclassification error = 0.2). CONCLUSION: Our study supports the use of this new technology, as well as the use of antibody profiles/patterns (rather than single antibody measures) as biomarkers of neutralizing antibody response and correlates of protective immunity in rubella virus serology. Public Library of Science 2017-11-16 /pmc/articles/PMC5690594/ /pubmed/29145521 http://dx.doi.org/10.1371/journal.pone.0188149 Text en © 2017 Haralambieva et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Haralambieva, Iana H.
Gibson, Michael J.
Kennedy, Richard B.
Ovsyannikova, Inna G.
Warner, Nathaniel D.
Grill, Diane E.
Poland, Gregory A.
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology
title Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology
title_full Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology
title_fullStr Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology
title_full_unstemmed Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology
title_short Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology
title_sort characterization of rubella-specific humoral immunity following two doses of mmr vaccine using proteome microarray technology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690594/
https://www.ncbi.nlm.nih.gov/pubmed/29145521
http://dx.doi.org/10.1371/journal.pone.0188149
work_keys_str_mv AT haralambievaianah characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology
AT gibsonmichaelj characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology
AT kennedyrichardb characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology
AT ovsyannikovainnag characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology
AT warnernathanield characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology
AT grilldianee characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology
AT polandgregorya characterizationofrubellaspecifichumoralimmunityfollowingtwodosesofmmrvaccineusingproteomemicroarraytechnology